These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Adinazolam, diazepam, imipramine, and placebo in major depressive disorder: a controlled study. Rickels K; London J; Fox I; Hassman H; Csanalosi I; Weise C Pharmacopsychiatry; 1991 Jul; 24(4):127-31. PubMed ID: 1754608 [TBL] [Abstract][Full Text] [Related]
3. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. Schweizer E; Feighner J; Mandos LA; Rickels K J Clin Psychiatry; 1994 Mar; 55(3):104-8. PubMed ID: 8071246 [TBL] [Abstract][Full Text] [Related]
4. Can mildly depressed outpatients with atypical depression benefit from antidepressants? Stewart JW; McGrath PJ; Quitkin FM Am J Psychiatry; 1992 May; 149(5):615-9. PubMed ID: 1575250 [TBL] [Abstract][Full Text] [Related]
5. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. Khan A; Brodhead AE; Kolts RL; Brown WA J Psychiatr Res; 2005 Mar; 39(2):145-50. PubMed ID: 15589562 [TBL] [Abstract][Full Text] [Related]
6. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. Fabre LF J Clin Psychiatry; 1992 Feb; 53 Suppl():40-3. PubMed ID: 1531823 [TBL] [Abstract][Full Text] [Related]
7. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. Dominguez RA; Goldstein BJ; Jacobson AF; Steinbook RM J Clin Psychiatry; 1985 Mar; 46(3):84-7. PubMed ID: 3918993 [TBL] [Abstract][Full Text] [Related]
8. A double-blind comparison of paroxetine, imipramine, and placebo in major depression. Shrivastava RK; Shrivastava SH; Overweg N; Blumhardt CL J Clin Psychiatry; 1992 Feb; 53 Suppl():48-51. PubMed ID: 1531825 [TBL] [Abstract][Full Text] [Related]
9. Chronic depression: response to placebo, imipramine, and phenelzine. Stewart JW; McGrath PJ; Quitkin FM; Rabkin JG; Harrison W; Wager S; Nunes E; Ocepek-Welikson K; Tricamo E J Clin Psychopharmacol; 1993 Dec; 13(6):391-6. PubMed ID: 8120152 [TBL] [Abstract][Full Text] [Related]
10. Comparison of adinazolam, amitriptyline, and diazepam in endogenous depressive inpatients exhibiting DST nonsuppression or abnormal contingent negative variation. Ansseau M; Devoitille JM; Papart P; Vanbrabant E; Mantanus H; Timsit-Berthier M J Clin Psychopharmacol; 1991 Jun; 11(3):160-5. PubMed ID: 2066454 [TBL] [Abstract][Full Text] [Related]
11. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901 [TBL] [Abstract][Full Text] [Related]
12. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. Khin NA; Chen YF; Yang Y; Yang P; Laughren TP J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123 [TBL] [Abstract][Full Text] [Related]
13. Adinazolam--a new antidepressant: findings of a placebo-controlled, double-blind study in outpatients with major depression. Dunner D; Myers J; Khan A; Avery D; Ishiki D; Pyke R J Clin Psychopharmacol; 1987 Jun; 7(3):170-2. PubMed ID: 3298327 [TBL] [Abstract][Full Text] [Related]
14. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Feighner JP; Boyer WF J Clin Psychiatry; 1992 Feb; 53 Suppl():44-7. PubMed ID: 1531824 [TBL] [Abstract][Full Text] [Related]
15. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine. Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053 [TBL] [Abstract][Full Text] [Related]
16. Efficacy in long-term treatment of depression. Montgomery SA J Clin Psychiatry; 1996; 57 Suppl 2():24-30. PubMed ID: 8626360 [TBL] [Abstract][Full Text] [Related]
17. Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease. Moonen AJ; Wijers A; Leentjens AF; Christine CW; Factor SA; Juncos J; Lyness JM; Marsh L; Panisset M; Pfeiffer R; Rottenberg D; Serrano Ramos C; Shulman L; Singer C; Slevin J; McDonald W; Auinger P; Richard IH Parkinsonism Relat Disord; 2014 Jun; 20(6):644-6. PubMed ID: 24679737 [TBL] [Abstract][Full Text] [Related]
18. Melancholic/endogenous depression and response to somatic treatment and placebo. Peselow ED; Sanfilipo MP; Difiglia C; Fieve RR Am J Psychiatry; 1992 Oct; 149(10):1324-34. PubMed ID: 1388334 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. Weisler RH; Montgomery SA; Earley WR; Szamosi J; Lazarus A Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845 [TBL] [Abstract][Full Text] [Related]
20. Nefazodone: aspects of efficacy. Rickels K; Robinson DS; Schweizer E; Marcus RN; Roberts DL J Clin Psychiatry; 1995; 56 Suppl 6():43-6. PubMed ID: 7649973 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]